Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Prednisolone
Accession Number
DB00860  (APRD00197)
Type
Small Molecule
Groups
Approved, Vet approved
Description

Prednisolone is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.4

Prednisolone was granted FDA approval on 21 June 1955.6

Structure
Thumb
Synonyms
  • (11β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione
  • 1,4-pregnadiene-11β,17α,21-triol-3,20-dione
  • 1,4-pregnadiene-3,20-dione-11β,17α,21-triol
  • 3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
  • delta-dehydrocortisol
  • delta-dehydrohydrocortisone
  • delta-hydrocortisone
  • delta(1)-Dehydrocortisol
  • delta(1)-Dehydrohydrocortisone
  • delta(1)-Hydrocortisone
  • Hydroretrocortine
  • Metacortandralone
  • PRDL
  • Prednisolona
  • Prednisolone
  • Prednisolonum
External IDs
NSC-9120 / NSC-9900
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PediapredSolution5 mgOralSanofi Aventis1998-09-23Not applicableCanada
Pediapred - Liq 6.7mg/5mlLiquidOralFisons1995-12-311998-08-12Canada
PrednisoLONESyrup15 mg/5mLOralVintage Pharmaceuticals, LLC2007-12-132007-12-13Us
PrednisoloneTablet5 mg/1OralWatson Pharmaceuticals2007-03-31Not applicableUs
PrednisoloneSyrup5 mg/5mLOralKV Pharmaceuticals2006-12-26Not applicableUs
PrednisoLONESolution15 mg/5mLOralPharmaceutical Associates, Inc.2007-08-09Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MillipredTablet5 mg/1OralCerecor, Inc.2014-03-01Not applicableUs
MillipredTablet5 mg/5mgOralLaser Pharmaceuticals Llc2008-10-012017-07-03Us16477 0505 01 nlmimage10 851b42ca
Novo-prednisolone 5mgTabletOralNovopharm Limited1967-12-312005-08-10Canada
PMS-prednisoloneSolutionOralPharmascience Inc2002-03-19Not applicableCanada
PrednisoloneSyrup5 mg/5mLOralPhysicians Total Care, Inc.2003-02-28Not applicableUs
PrednisoLONESyrup15 mg/5mLOralPreferreed Pharmaceuticals Inc.2018-07-23Not applicableUs
PrednisoLONESyrup15 mg/5mLOralPreferreed Pharmaceuticals Inc.2013-10-25Not applicableUs
PrednisoloneSolution15 mg/5mLOralDispensing Solutions, Inc.2003-02-27Not applicableUs
PrednisoloneSolution15 mg/5mLOralAidarex Pharmaceuticals LLC1998-12-11Not applicableUs
PrednisoloneSolution15 mg/5mLOralA-S Medication Solutions2003-02-27Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
CambisonPrednisolone (4 mg/1g) + Neomycin sulfate (3 mg/1g)OintmentTopicalOASIS TRADING2018-11-15Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
CambisonPrednisolone (4 mg/1g) + Neomycin sulfate (3 mg/1g)OintmentTopicalOASIS TRADING2018-11-15Not applicableUs
International/Other Brands
Ak-Pred / Decortin H / Delta-Cortef / Deltacortril / Hydeltra / Hydeltra-TBA / Hydeltrasol / Inflamase / Key-Pred / Klismacort / Meticortelone / Panafcortelone / Predonine / Prelone / Solone / Sterolone / Ultracortenol
Categories
UNII
9PHQ9Y1OLM
CAS number
50-24-8
Weight
Average: 360.444
Monoisotopic: 360.193674006
Chemical Formula
C21H28O5
InChI Key
OIGNJSKKLXVSLS-VWUMJDOOSA-N
InChI
InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
IUPAC Name
(1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-1-(2-hydroxyacetyl)-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

Pharmacology

Indication

Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.7

Associated Conditions
Pharmacodynamics

Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals.4 Prednisolone has a short duration of action as the half life is 2.1-3.5 hours.1 Corticosteroids have a wide therapeutic window as patients make require doses that are multiples of what the body naturally produces.4 Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.4

Mechanism of action

The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation.4 Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days.4

Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10.4

Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive.4 High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels.4

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Oral prednisolone reaches a Cmax of 113-1343ng/mL with a Tmax of 1.0-2.6 hours.1 Oral prednisolone is approximately 70% bioavailable.2

Volume of distribution

A 0.15mg/kg dose of prednisolone has a volume of distribution of 29.3L, while a 0.30mg/kg dose has a volume of distribution of 44.2L.1

Protein binding

Prednisolone's protein binding is highly variable, ranging from 65-91% in healthy patients.1

Metabolism

Prednisolone can be reversibly metabolized to prednisone which is then metabolized to 17α,21-dihydroxy-pregnan-1,4,6-trien-3,11,30-trione (M-XVII), 20α-dihydro-prednisone (M-V), 6βhydroxy-prednisone (M-XII), 6α-hydroxy-prednisone (M-XIII), or 20β-dihydro-prednisone (M-IV).3 20β-dihydro-prednisone is metabolized to 17α,20ξ,21-trihydroxy-5ξ-pregn-1-en-3,11-dione(M-XVIII).3 Prednisolone is metabolized to Δ6-prednisolone (M-XI), 20α-dihydro-prednisolone (M-III), 20β-dihydro-prednisolone (M-II), 6αhydroxy-prednisolone (M-VII), or 6βhydroxy-prednisolone(M-VI).3 6αhydroxy-prednisolone is metabolized to 6α,11β,17α,20β,21-pentahydroxypregnan-1,4-diene-3-one (M-X).3 6βhydroxy-prednisolone is metabolized to 6β,11β,17α,20β,21-pentahydroxypregnan-1,4-diene-3-one (M-VIII), 6β,11β,17α,20α,21-pentahydroxypregnan-1,4-diene-3-one (M-IX), and 6β,11β,17α,21-tetrahydroxy-5ξ-pregn-1-en-3,20-dione (M-XIV).3 MVIII is metabolized to 6β,11β,17α,20β,21-pentahydroxy-5ξ-pregn-1-en-3-one (M-XV) and then to MXIV, while MIX is metabolized to 6β,11β,17α,20α,21-pentahydroxy-5ξ-pregn-1-en-3-one (M-XVI) and then to MXIV.3 These metabolites and their glucuronide conjugates are excreted predominantly in the urine.3

Route of elimination

Prednisolone is over 98% eliminated in urine.1

Half life

Prednisolone has a plasma half life of 2.1-3.5 hours.1 This half life is shorter in children and longer in those with liver disease.1

Clearance

A 0.15mg/kg dose of prednisolone has a clearance of 0.09L/kg/h, while a 0.30mg/kg dose has a clearance of 0.12L/kg/h.1

Toxicity

The intraperitoneal LD50 in rats is 2g/kg and 65mg/kg in mice.8 The subcutaneous LD50 in rats is 147mg/kg and >3500mg/kg in mice.8 The oral LD50 in mice is 1680mg/kg.8 In humans, the oral TDLO in men is 9mg/kg/2W and in women is 14mg/kg/13D.8

Patients experiencing an overdose of prednisolone may present with gastrointestinal disturbances, insomnia, and restlessness.5 Overdose of oral prednisolone may be treated by gastric lavage or inducing vomiting if the overdose was recent, as well as supportive and symptomatic therapy.9 Chronic overdosage may be treated by dose reduction or treating patients on alternate days.9 An overdose by the ophthalmic route is not expected to cause problems.9

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Prednisone Action PathwayDrug action
Prednisolone Action PathwayDrug action
Prednisone Metabolism PathwayDrug metabolism
Prednisolone Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be increased when combined with Prednisolone.
(S)-WarfarinThe metabolism of (S)-Warfarin can be increased when combined with Prednisolone.
1-TestosteroneThe risk or severity of edema formation can be increased when 1-Testosterone is combined with Prednisolone.
1,10-PhenanthrolineThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Prednisolone.
16-BromoepiandrosteroneThe risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Prednisolone.
19-norandrostenedioneThe risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Prednisolone.
1alpha-Hydroxyvitamin D5The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Prednisolone.
1alpha,24S-Dihydroxyvitamin D2The therapeutic efficacy of 1alpha,24S-Dihydroxyvitamin D2 can be decreased when used in combination with Prednisolone.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when Prednisolone is combined with 2-Methoxyethanol.
2,4-thiazolidinedioneThe risk or severity of hyperglycemia can be increased when Prednisolone is combined with 2,4-thiazolidinedione.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Avoid alcohol. Avoid caffeine.
  • Take with food to reduce gastric irritation.

References

Synthesis Reference

Gunther Bellmann, "Process for producing a sterile prednisolone gel." U.S. Patent US5811417, issued September 22, 1998.

US5811417
General References
  1. Pickup ME: Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet. 1979 Mar-Apr;4(2):111-28. doi: 10.2165/00003088-197904020-00004. [PubMed:378499]
  2. Ferry JJ, Horvath AM, Bekersky I, Heath EC, Ryan CF, Colburn WA: Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. J Clin Pharmacol. 1988 Jan;28(1):81-7. doi: 10.1002/j.1552-4604.1988.tb03105.x. [PubMed:3350994]
  3. Matabosch X, Pozo OJ, Perez-Mana C, Papaseit E, Segura J, Ventura R: Detection and characterization of prednisolone metabolites in human urine by LC-MS/MS. J Mass Spectrom. 2015 Mar;50(3):633-42. doi: 10.1002/jms.3571. [PubMed:25800201]
  4. Yasir M, Sonthalia S: Corticosteroid Adverse Effects . [PubMed:30285357]
  5. Robinson J, McKenzie C, MacLeod D: Paediatric dosing errors with oral prednisolone mixture. Aust Prescr. 2016 Oct;39(5):176. doi: 10.18773/austprescr.2016.062. Epub 2016 Oct 1. [PubMed:27789930]
  6. FDA Approved Drug Products: Delta-Cortef Prednisolone Oral Tablets (Discontinued) [Link]
  7. FDA Approved Drug Products: Prednisolone Oral Syrup [Link]
  8. Cayman Chemicals: Prednisolone MSDS [Link]
  9. FDA Approved Drug Products: Prednisolone Acetate Oral Suspension [Link]
  10. FDA Approved Drug Products: Prednisolone Acetate Ophthalmic Suspension [Link]
  11. FDA Approved Drug Products: Orapred Prednisolone Sodium Phosphate Orally Disintegrating Tablets [Link]
  12. FDA Approved Drug Products: Pediapred Prednisolons Sodium Phosphate Oral Solution [Link]
External Links
Human Metabolome Database
HMDB0014998
KEGG Drug
D00472
KEGG Compound
C07369
PubChem Compound
5755
PubChem Substance
46504847
ChemSpider
5552
BindingDB
19190
ChEBI
8378
ChEMBL
CHEMBL131
Therapeutic Targets Database
DAP000419
PharmGKB
PA451096
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Prednisolone
ATC Codes
S01CA02 — Prednisolone and antiinfectivesD07AA03 — PrednisoloneD07XA02 — PrednisoloneA01AC54 — Prednisolone, combinationsR01AD02 — PrednisoloneS01BB02 — Prednisolone and mydriaticsR01AD52 — Prednisolone, combinationsS01CB02 — PrednisoloneV03AB05 — Prednisolone and promethazineS03BA02 — PrednisoloneD07BA01 — Prednisolone and antisepticsD07CA03 — Prednisolone and antibioticsS01BA04 — PrednisoloneS02BA03 — PrednisoloneA07EA01 — PrednisoloneH02AB06 — PrednisoloneS02CA01 — Prednisolone and antiinfectivesC05AA04 — PrednisoloneS03CA02 — Prednisolone and antiinfectives
AHFS Codes
  • 68:04.00 — Adrenals
FDA label
Download (101 KB)
MSDS
Download (72.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0WithdrawnDiagnosticSevere Alcoholic Hepatitis1
1CompletedBasic ScienceChronic Obstructive Pulmonary Disease (COPD) / Healthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers / Pharmacodynamics / Pharmacokinetics / Rheumatoid Arthritis / Safety / Tolerability1
1CompletedBasic ScienceImmunoscience1
1CompletedBasic ScienceMalignant Lymphomas1
1CompletedOtherInflammatory Reaction1
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)3
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentMultiple Myeloma (MM)1
1CompletedTreatmentProstate Cancer1
1CompletedTreatmentRheumatoid Arthritis1
1CompletedTreatmentStatus Asthmaticus1
1Not Yet RecruitingTreatmentCancer, Advanced1
1RecruitingPreventionEsophageal Anastomotic Stricture1
1RecruitingTreatmentLeukemia, Acute / Leukemia, Lymphocytic / Leukemia, T-Cell / Lymphoma, Lymphoblastic / Recurrent Disease / T-Cell Lymphomas1
1RecruitingTreatmentMuscular Dystrophy, Duchenne1
1RecruitingTreatmentWet Age-Related Macular Degeneration1
1TerminatedTreatmentAsthma1
1TerminatedTreatmentFollicular Lymphoma (FL)1
1Unknown StatusTreatmentLymphoma, Hodgkins1
1Unknown StatusTreatmentMalignant Lymphomas1
1Unknown StatusTreatmentMalignant Lymphomas / Small Intestine Cancer1
1, 2Active Not RecruitingTreatmentComplete Atypical DiGeorge Anomaly / Complete Atypical DiGeorge Syndrome / Complete DiGeorge Anomaly / Complete DiGeorge Syndrome / DiGeorge Anomaly1
1, 2Active Not RecruitingTreatmentDiffuse B-Cell Lymphoma1
1, 2Active Not RecruitingTreatmentProstate Cancer1
1, 2CompletedBasic ScienceHealthy Volunteers1
1, 2CompletedTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T Cell Lymphoma / Cutaneous T Cell Lymphomas (CTCL) / Peripheral T Cell Lymphoma Unspecified1
1, 2CompletedTreatmentLipomas1
1, 2CompletedTreatmentLymphoma, B-Cell, Non-Hodgkin's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentLymphoma, B-Cell / Lymphoma, Large-Cell, Diffuse1
1, 2CompletedTreatmentProstate Cancer1
1, 2CompletedTreatmentProstate Neoplasms1
1, 2CompletedTreatmentTraumatic Optic Neuropathy1
1, 2RecruitingTreatmentHemophagocytic Lymphohistiocytosis (HLH)1
1, 2RecruitingTreatmentLeber Congenital Amaurosis (LCA)1
1, 2RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1, 2RecruitingTreatmentOrnithine Transcarbamylase (OTC) Deficiency1
1, 2SuspendedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2Unknown StatusTreatmentAtherosclerosis / Inflammatory Reaction1
1, 2Unknown StatusTreatmentMalignant Lymphomas1
2Active Not RecruitingSupportive CareLymphoma, Large B-Cell, Diffuse (DLBCL)2
2Active Not RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T-Cell Lymphoma / Enteropathy-Associated T-Cell Lymphoma / Hepatosplenic Gamma/ Delta T-cell Lymphoma / Peripheral T-cell Lymphoma NOS1
2Active Not RecruitingTreatmentEpstein-Barr Virus-positive Diffuse Large B-cell Lymphoma1
2Active Not RecruitingTreatmentLarge B-cell Diffuse Lymphoma of Testis / Primary Testicular Diffuse Large B-cell Lymphoma1
2Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
2Active Not RecruitingTreatmentLymphoma, Lymphoblastic1
2Active Not RecruitingTreatmentLymphoproliferative Disorders1
2Active Not RecruitingTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
2Active Not RecruitingTreatmentStage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
2Active Not RecruitingTreatmentSteroids In Management Of Acute Asthma Exacerbations1
2CompletedNot AvailableAsthma1
2CompletedBasic ScienceWhole Body Catabolisme Induced by Glucocorticoids1
2CompletedSupportive CarePost Operative Nausea and Vomiting (PONV) / Postoperative pain1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2CompletedTreatmentAlcoholic Hepatitis (AH)2
2CompletedTreatmentBronchial Asthma1
2CompletedTreatmentConnective Tissue Diseases / Dermatomyositis / Vasculitis / Vasculitis, Hypersensitivity1
2CompletedTreatmentDuchenne's Muscular Dystrophy (DMD)1
2CompletedTreatmentFollicular Lymphoma (FL)1
2CompletedTreatmentGranulomatosis With Polyangiitis / Microscopic Polyangiitis / Renal Limited Vasculitis1
2CompletedTreatmentHIV Disease Progression1
2CompletedTreatmentHansen's Disease2
2CompletedTreatmentHormone Refractory / Metastatic / Prostate Cancer1
2CompletedTreatmentHormone-Refractory Prostate Cancer1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis Infection1
2CompletedTreatmentLeukemias1
2CompletedTreatmentLymphoma, B-Cell1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2CompletedTreatmentMalignant Lymphomas3
2CompletedTreatmentMalignant Lymphomas / Neurologic toxicity1
2CompletedTreatmentMelanoma1
2CompletedTreatmentMetastatic Cancers / Prostate Cancer1
2CompletedTreatmentMetastatic ER+ Her2- Breast Cancer / One to five years postmenopausal1
2CompletedTreatmentNephritis, Lupus2
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentOvarian Cancer / Prostate Cancer1
2CompletedTreatmentProstate Cancer3
2CompletedTreatmentRheumatoid Arthritis6
2Enrolling by InvitationTreatmentBecker's Muscular Dystrophy (BMD) / Limb-Girdle Muscular Dystrophies1
2Not Yet RecruitingTreatmentAsthma / Chronic Obstructive Pulmonary Disease (COPD)1
2Not Yet RecruitingTreatmentRichter's Syndrome1
2RecruitingTreatmentAcute Leukemias of Ambiguous Lineage / B Acute Lymphoblastic Leukemia / Childhood B Acute Lymphoblastic Leukemia / KMT2A Gene Rearrangement / Mixed Phenotype Acute Leukemia (MPAL)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Childhood Cancers / Down Syndrome (DS)1
2RecruitingTreatmentAlcoholic Hepatitis (AH)1
2RecruitingTreatmentAutoimmune Diseases1
2RecruitingTreatmentCerebral Radiation Necrosis1
2RecruitingTreatmentCognitive Change / Immune Suppression / Psychosis / Schizophrenia and Related Disorders1
2RecruitingTreatmentEBV-Positive DLBCL, Nos1
2RecruitingTreatmentGiant Cells Arteritis1
2RecruitingTreatmentHigh Risk Localised Prostate Carcinoma1
2RecruitingTreatmentIatrogenic Cushing's Disease1
2RecruitingTreatmentKaposiform Hemangioendothelioma / Kasabach Merritt Phenomenon1
2RecruitingTreatmentKidney Transplant Rejection1
2RecruitingTreatmentLymphoma, Hodgkins2
2RecruitingTreatmentMetastatic Castration-Resistant Prostate Cancer Patients1
2RecruitingTreatmentMyocardial Inflammation1
2RecruitingTreatmentNon-arteritic Anterior Ischemic Optic Neuropathy (NAION)1
2RecruitingTreatmentRheumatoid Arthritis1
2RecruitingTreatmentSclerosis, Progressive Systemic1
2SuspendedTreatmentAllergic Alveolitis1
2TerminatedBasic ScienceDependence, Cocaine / Opioid Dependence1
2TerminatedTreatmentHemangiomas1
2TerminatedTreatmentHemangiomas of Infancy1
2TerminatedTreatmentHemodynamics / Neointima / Renal Dialysis / Vascular Remodeling1
2TerminatedTreatmentKnee Osteoarthritis (Knee OA)1
2TerminatedTreatmentMultiple Myeloma (MM)1
2TerminatedTreatmentRheumatoid Arthritis1
2Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2Unknown StatusTreatmentAnemia, Hemolytic, Autoimmune / Anemias / Autoimmune Diseases / Hematologic Diseases / Hemolysis / Hemolytic Anemia / Immune System Diseases / Pathologic Processes1
2Unknown StatusTreatmentBreast Cancer1
2Unknown StatusTreatmentLeukemias3
2Unknown StatusTreatmentMalignant Lymphomas2
2Unknown StatusTreatmentMalignant Lymphomas / Small Intestine Cancer1
2Unknown StatusTreatmentRenal Insufficiency,Chronic / Transplantation, Liver1
2Unknown StatusTreatmentStomatitis, Aphthous1
2WithdrawnTreatmentAcute Interstitial Nephritis1
2WithdrawnTreatmentAsthma1
2WithdrawnTreatmentLPL Deficiency1
2, 3CompletedDiagnosticRheumatoid Arthritis1
2, 3CompletedOtherInfertility1
2, 3CompletedTreatmentAspergillosis, Allergic Bronchopulmonary2
2, 3CompletedTreatmentGluten Enteropathy1
2, 3CompletedTreatmentHansen's Disease1
2, 3CompletedTreatmentInfertility1
2, 3CompletedTreatmentPolymyalgia Rheumatica1
2, 3CompletedTreatmentPost-operative Endodontic Pain1
2, 3Not Yet RecruitingTreatmentIgA Nephropathy1
2, 3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Lymphoblastic Lymphoma1
2, 3RecruitingTreatmentBell's Palsy / Facial Nerve Paresis1
2, 3RecruitingTreatmentIgA Nephropathy at High Risk of Developing ESRD / Progressive IgA Nephropathy1
2, 3RecruitingTreatmentProstate Cancer1
2, 3RecruitingTreatmentThrombotic Thrombocytopenic Purpura (TTP)1
2, 3TerminatedTreatmentGranulomatosis With Polyangiitis / Microscopic Polyangiitis1
2, 3TerminatedTreatmentSystemic Lupus Erythematosus (SLE)1
2, 3Unknown StatusTreatmentAnkylosing Spondylitis (AS)1
2, 3Unknown StatusTreatmentOsteoarthritis (OA)1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3Active Not RecruitingTreatmentAlcoholic Hepatitis (AH) / Severe alcoholic liver disease1
3Active Not RecruitingTreatmentAsthma1
3Active Not RecruitingTreatmentChurg-Strauss Syndrome (CSS)1
3Active Not RecruitingTreatmentFollicular Lymphoma (FL)1
3Active Not RecruitingTreatmentImmune Thrombocytopenia1
3Active Not RecruitingTreatmentMalignant Lymphomas2
3Active Not RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
3Active Not RecruitingTreatmentProgression of Rheumatoid Arthritis1
3Active Not RecruitingTreatmentProstatic Neoplasms1
3CompletedPreventionAcute Urinary Tract Infection / Urinary Tract Infection1
3CompletedPreventionTransplantation, Kidney1
3CompletedSupportive CarePulpitis dental1
3CompletedTreatmentActive Rheumatoid Arthritis (RA)1
3CompletedTreatmentAcute Exacerbation of Chronic Obstructive Pulmonary Disease1
3CompletedTreatmentAlcoholic Hepatitis (AH) / Severe alcoholic liver disease1
3CompletedTreatmentAllergic Rhinitis (AR)1
3CompletedTreatmentAnemia, Hemolytic, Autoimmune1
3CompletedTreatmentAsthma4
3CompletedTreatmentAsthma / Wheezing1
3CompletedTreatmentCarcinoma NOS / Malignancies / Malignant Ascites / Neoplasms1
3CompletedTreatmentCataracts1
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
3CompletedTreatmentCongenital Adrenal Hyperplasia (CAH)1
3CompletedTreatmentDermatitis, Eczematous1
3CompletedTreatmentDermatomyositis / Polymyositis1
3CompletedTreatmentDiffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma1
3CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Leukemias1
3CompletedTreatmentEye Infections / Postoperative Complications1
3CompletedTreatmentFollicular Lymphoma (FL)1
3CompletedTreatmentGlomerulonephritis, Membranous1
3CompletedTreatmentGlomerulonephritis, Membranous / Glomerulosclerosis, Focal Segmental1
3CompletedTreatmentGlomerulonephritis, Membranous / Nephritis, Lupus1
3CompletedTreatmentHeadache1
3CompletedTreatmentHemangiomas1
3CompletedTreatmentHepatocellular,Carcinoma1
3CompletedTreatmentHypereosinophilic Syndromes1
3CompletedTreatmentIdiopathic Thrombocytopenic Purpura1
3CompletedTreatmentInfantile Spasms (IS)1
3CompletedTreatmentInfantile Spasms (IS) / West Syndrome1
3CompletedTreatmentKidney Diseases1
3CompletedTreatmentLeukemias3
3CompletedTreatmentLeukemias / Malignant Lymphomas2
3CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
3CompletedTreatmentMalignant Lymphomas5
3CompletedTreatmentMultiple Myeloma (MM)2
3CompletedTreatmentMyasthenia Gravis1
3CompletedTreatmentNeoplasms Metastasis / Prostatic Neoplasms1
3CompletedTreatmentProstate Cancer1
3CompletedTreatmentProstate Neoplasms1
3CompletedTreatmentProstatic Neoplasms1
3CompletedTreatmentRheumatoid Arthritis1
3CompletedTreatmentTransplantation, Renal1
3CompletedTreatmentTuberculous Pericarditis1
3CompletedTreatmentUlcerative Colitis1
3Enrolling by InvitationTreatmentGlaucoma1
3Not Yet RecruitingPreventionTransplantation, Liver1
3Not Yet RecruitingTreatmentArterial Ischemic Stroke1
3Not Yet RecruitingTreatmentIdiopathic orbital inflammation1
3Not Yet RecruitingTreatmentMucocutaneous Lymph Node Syndrome1
3RecruitingTreatmentANCA Associated Vasculitis1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
3RecruitingTreatmentAcute Lymphoblastic Leukemia, Pediatric1
3RecruitingTreatmentAdrenal Insufficiency1
3RecruitingTreatmentAlcoholic Hepatitis (AH)1
3RecruitingTreatmentAlcoholic Hepatitis (AH) / Infection NOS1
3RecruitingTreatmentAsthma2
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / B Lymphoblastic Lymphoma / Blasts More Than 25 Percent of Bone Marrow Nucleated Cells / Central Nervous System Leukemia / Mixed Phenotype Acute Leukemia (MPAL) / Testicular Leukemia1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / B Lymphoblastic Lymphoma / Blasts More Than 25 Percent of Bone Marrow Nucleated Cells / Down Syndrome (DS)1
3RecruitingTreatmentDisseminated Sclerosis1
3RecruitingTreatmentGlomerulosclerosis, Focal Segmental / Idiopathic Nephrotic Syndrome / Nephrotic Syndrome1
3RecruitingTreatmentGraves Diseases / Hyperthyroidism1
3RecruitingTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
3RecruitingTreatmentImmuoglobulin / Mucocutaneous Lymph Node Syndrome / Steroid1
3RecruitingTreatmentLymphoblastic Lymphoma, Childhood1
3RecruitingTreatmentMature B-cell Non-Hodgkin Lymphoma1
3RecruitingTreatmentNephrotic Syndrome1
3RecruitingTreatmentOcular Hypertension / Open Angle Glaucoma (OAG)1
3RecruitingTreatmentPolymyalgia Rheumatica1
3RecruitingTreatmentRecurrent Miscarriages1
3SuspendedTreatmentCongenital Adrenal Hyperplasia (CAH)1
3TerminatedHealth Services ResearchFollicular Lymphoma (FL)1
3TerminatedTreatmentCrohn's Disease (CD)1
3TerminatedTreatmentCroup1
3TerminatedTreatmentCutaneous Hypersensitivity1
3TerminatedTreatmentEvidence of Liver Transplantation / Transplantations1
3TerminatedTreatmentMalignant Lymphomas1
3TerminatedTreatmentNephritis, Lupus1
3TerminatedTreatmentPemphigus1
3TerminatedTreatmentSystemic Lupus Erythematosus, Lupus Nephritis1
3TerminatedTreatmentUlcerative Colitis1
3Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3Unknown StatusTreatmentAlcoholic Hepatitis (AH)1
3Unknown StatusTreatmentAllergic Rhinitis (AR)1
3Unknown StatusTreatmentBiliary Atresia1
3Unknown StatusTreatmentChorioretinitis1
3Unknown StatusTreatmentECD / Expanded Criteria Donor / Transplantation of Kidney1
3Unknown StatusTreatmentEye Infection/Inflammation Other1
3Unknown StatusTreatmentFollicular Lymphoma (FL)1
3Unknown StatusTreatmentLeukemias1
3Unknown StatusTreatmentLeukemias / Malignant Lymphomas1
3Unknown StatusTreatmentMalignant Lymphomas3
3Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
3Unknown StatusTreatmentRheumatoid Arthritis1
3WithdrawnTreatmentInfantile Spasms (IS)1
3WithdrawnTreatmentNephritis, Lupus1
4Active Not RecruitingPreventionPostoperative Cystoid Macular Edema / Pseudophakic Cystoid Macular Edema1
4Active Not RecruitingTreatmentCrohn's Disease (CD)1
4Active Not RecruitingTreatmentFunction of Renal Transplant1
4Active Not RecruitingTreatmentProstate Cancer1
4Active Not RecruitingTreatmentRheumatoid Arthritis2
4Active Not RecruitingTreatmentSeasonal Allergic Rhinitis (SAR)1
4CompletedDiagnosticCoughing1
4CompletedOtherAsthma1
4CompletedPreventionAdverse Effects / Transplantation, Kidney1
4CompletedPreventionChronic Allergic Conjunctivitis1
4CompletedPreventionConjunctivitis, Seasonal Allergic1
4CompletedPreventionRenal Transplant Recipient Patients1
4CompletedPreventionTracheal Stenosis1
4CompletedPreventionTransplantation, Kidney1
4CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4CompletedTreatmentAdult Acute Lymphocytic Leukemia3
4CompletedTreatmentAsthma3
4CompletedTreatmentAsthma / Asthma Acute1
4CompletedTreatmentAsthma / Asthma Acute / Reactive Airway Exacerbation1
4CompletedTreatmentAtopic Dermatitis (AD)1
4CompletedTreatmentBell's Palsy1
4CompletedTreatmentBlood Eosinophil Count / Chronic Obstructive Pulmonary Disease (COPD) / Glucocorticoid therapy / Lung Diseases, Obstructive1
4CompletedTreatmentBurkitt's Lymphoma / Large Cell Anaplastic Lymphoma / Lymphoma, Lymphoblastic / Mediastinal Neoplasms1
4CompletedTreatmentCataracts / Dry Eye Syndromes1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)2
4CompletedTreatmentChronic Renal Diseases1
4CompletedTreatmentCorticotropin Deficiency / Fasting1
4CompletedTreatmentDisease, Chronic / Idiopathic eosinophilic pneumonias1
4CompletedTreatmentDrug Interaction Potentiation / Transplantation, Kidney1
4CompletedTreatmentGlaucoma1
4CompletedTreatmentHemangiomas1
4CompletedTreatmentImmunoglobulin G4 Related Sclerosing Disease1
4CompletedTreatmentJuvenile Chronic Polyarthritis / Juvenile Idiopathic Arthritis (JIA) / Rheumatoid Arthritis, Juvenile1
4CompletedTreatmentKnee Osteoarthritis (Knee OA)1
4CompletedTreatmentLymphoma, Lymphoblastic1
4CompletedTreatmentMCNS / Minimal Change Nephrotic Syndrome (MCNS)1
4CompletedTreatmentMetastatic Castration Resistant Prostate Cancer1
4CompletedTreatmentMetastatic Hormone Refractory Prostate Cancer1
4CompletedTreatmentNephritis, Lupus2
4CompletedTreatmentNephrotic Syndrome2
4CompletedTreatmentOptic Disk / Regional Blood Flow1
4CompletedTreatmentOral Lichen Planus1
4CompletedTreatmentPain1
4CompletedTreatmentPolyps, Nasal1
4CompletedTreatmentProstate Cancer1
4CompletedTreatmentPulpitis dental1
4CompletedTreatmentRejection, Transplant / Renal Failure / Transplantation, Kidney1
4CompletedTreatmentRenal Function1
4CompletedTreatmentRheumatoid Arthritis1
4CompletedTreatmentSepsis1
4CompletedTreatmentImpaired kidney function / Transplantation, Kidney1
4CompletedTreatmentAcute fulminant liver failure1
4Not Yet RecruitingPreventionEsophageal Strictures / Esophagus, Barrett1
4Not Yet RecruitingTreatmentBenign Childhood Epilepsy With Centrotemporal Spikes1
4Not Yet RecruitingTreatmentEncephalitis, Viral1
4Not Yet RecruitingTreatmentMyopathies1
4RecruitingOtherAsthma1
4RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4RecruitingTreatmentAdvanced Follicular Lymphoma1
4RecruitingTreatmentAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Granulomatosis With Polyangiitis / Microscopic Polyangiitis1
4RecruitingTreatmentAsthma1
4RecruitingTreatmentBell's Palsy / Borrelia Infection of Central Nervous System / Facial Nerve Diseases / Facial Paralysis1
4RecruitingTreatmentCongenital Adrenal Hyperplasia (CAH)1
4RecruitingTreatmentEpilepsy, Unspecified, Intractable1
4RecruitingTreatmentIgA Nephropathy1
4RecruitingTreatmentInfertility / Polycystic Ovarian Syndrome1
4RecruitingTreatmentMalignant Lymphomas1
4RecruitingTreatmentMycoplasma Pneumoniae Pneumonia1
4RecruitingTreatmentNephrotic Syndrome1
4RecruitingTreatmentOphthalmopathy, Thyroid-Associated1
4RecruitingTreatmentRecurrent IgA Nephropathy1
4RecruitingTreatmentRheumatoid Arthritis1
4RecruitingTreatmentSarcoidosis1
4RecruitingTreatmentUlcerative Colitis1
4SuspendedTreatmentVestibular Diseases / Vestibular Neuronitis1
4TerminatedTreatmentAcute Respiratory Failure1
4TerminatedTreatmentImmune Reconstitution Inflammatory Syndrome / Progressive Multifocal Leukoencephalopathy1
4TerminatedTreatmentOSAS (Obstructive Sleep Apneas Syndrome)1
4TerminatedTreatmentPsychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
4Unknown StatusScreeningOcular Hypertension / Vitreoretinal Disease1
4Unknown StatusTreatmentAdult Acute Lymphocytic Leukemia2
4Unknown StatusTreatmentCrohn's Disease (CD)1
4Unknown StatusTreatmentDisorder Related to Renal Transplantation1
4Unknown StatusTreatmentHepatitis B Chronic Infection1
4Unknown StatusTreatmentNephrotic Syndrome1
4Unknown StatusTreatmentWheezing1
Not AvailableActive Not RecruitingBasic ScienceAsthma / Chronic Obstructive Pulmonary Disease (COPD)1
Not AvailableActive Not RecruitingTreatmentMalignant Lymphomas1
Not AvailableApproved for MarketingNot AvailableGenital Diseases, Male / Genital Neoplasms, Male / Genitourinary tract neoplasm / Prostate Neoplasms1
Not AvailableAvailableNot AvailableComplete DiGeorge Anomaly / Complete DiGeorge Syndrome / DiGeorge Anomaly / DiGeorge's syndrome1
Not AvailableCompletedNot AvailableHemangiomas1
Not AvailableCompletedBasic ScienceElectroretinography1
Not AvailableCompletedPreventionBeta-cell Function / Diabetes Mellitus (DM) / Glucocorticoid-induced Diabetes / Steroid Diabetes1
Not AvailableCompletedPreventionPatients With Systemic Inflammatory Diseases Receiving for the First Time a Protracted General Corticostroid Therapy1
Not AvailableCompletedTreatmentBiliary Atresia1
Not AvailableCompletedTreatmentCarpal Tunnel Syndrome (CTS)1
Not AvailableCompletedTreatmentCataracts1
Not AvailableCompletedTreatmentChildhood Langerhans Cell Histiocytosis1
Not AvailableCompletedTreatmentCorneal Neovascularization1
Not AvailableCompletedTreatmentDrug hypersensitivity reaction1
Not AvailableCompletedTreatmentFacial Paralysis1
Not AvailableCompletedTreatmentGlaucoma, Primary Open Angle (POAG) / Pseudoexfoliation Syndrome1
Not AvailableCompletedTreatmentGlucocorticoid-induced Beta-cell Dysfunction / Glucocorticoid-induced Glucometabolic Abnormalities1
Not AvailableCompletedTreatmentHyperglycemia / Impaired Glucose Tolerance / Insulin Resistance1
Not AvailableCompletedTreatmentIgA Nephropathy1
Not AvailableCompletedTreatmentModerate to Severe Atopic Dermatitis1
Not AvailableCompletedTreatmentOsteolymphoma1
Not AvailableCompletedTreatmentReproductive Sterility1
Not AvailableCompletedTreatmentScleral Buckling1
Not AvailableCompletedTreatmentTuberculous Pleurisy1
Not AvailableNot Yet RecruitingNot AvailableAsthma in Children1
Not AvailableNot Yet RecruitingNot AvailableTo Evaluate the Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma1
Not AvailableNot Yet RecruitingTreatmentErythema Nodosum Leprosum1
Not AvailableNot Yet RecruitingTreatmentTonsillectomy1
Not AvailableRecruitingNot AvailableChildren / Immunosuppressive Treatment / Nephritis, Lupus / Steroid1
Not AvailableRecruitingNot AvailableIgA Nephropathy / Immunosuppressive Treatment / Proteinuria in Nephrotic Range1
Not AvailableRecruitingNot AvailableProstatic Neoplasms1
Not AvailableRecruitingBasic ScienceInflammation; Skin1
Not AvailableRecruitingDiagnosticCardiac Sarcoidosis1
Not AvailableRecruitingDiagnosticSarcoidosis, Pulmonary1
Not AvailableRecruitingHealth Services ResearchHypospadias1
Not AvailableRecruitingTreatmentAlcoholic Hepatitis (AH)1
Not AvailableRecruitingTreatmentAllergies / Urticaria1
Not AvailableRecruitingTreatmentCorneal Graft Rejection1
Not AvailableRecruitingTreatmentDisorder Related to Renal Transplantation / Effects of Immunosuppressant Therapy1
Not AvailableRecruitingTreatmentLeukemias1
Not AvailableRecruitingTreatmentVentral Hernias1
Not AvailableTerminatedNot AvailableProstatic Neoplasms1
Not AvailableTerminatedTreatmentDrug Induced Liver Injury1
Not AvailableUnknown StatusNot AvailableExacerbation of asthma1
Not AvailableUnknown StatusNot AvailableScleritis / Uveitis1
Not AvailableUnknown StatusPreventionAsthma1
Not AvailableUnknown StatusSupportive CareNon-Hodgkin's Lymphoma (NHL)1
Not AvailableUnknown StatusTreatmentBehcet's Syndrome / Uveal Disease1
Not AvailableUnknown StatusTreatmentBell's Palsy1
Not AvailableUnknown StatusTreatmentLeukemias1
Not AvailableUnknown StatusTreatmentMalignant Lymphomas3
Not AvailableWithdrawnNot AvailableAcute Lymphoblastic Leukaemias (ALL) / Leukemias / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableWithdrawnTreatmentBronchiolitis1

Pharmacoeconomics

Manufacturers
  • Pharmacia and upjohn co
  • Akorn inc
  • Sandoz canada inc
  • Teva parenteral medicines inc
  • Watson laboratories inc
  • Bel mar laboratories inc
  • Schering corp sub schering plough corp
  • Alpharma uspd inc
  • Apotex inc richmond hill
  • Hi tech pharmacal co inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Vintage pharmaceuticals llc
  • We pharmaceuticals inc
  • Wockhardt eu operations (swiss) ag
  • Muro pharmaceutical inc
  • Teva pharmaceuticals usa inc
  • Halsey drug co inc
  • Ferndale laboratories inc
  • Barr laboratories inc
  • Cm bundy co
  • Elkins sinn div ah robins co inc
  • Everylife
  • John j ferrante
  • Heather drug co inc
  • Impax laboratories inc
  • Inwood laboratories inc sub forest laboratories inc
  • Lannett co inc
  • Marshall pharmacal corp
  • Panray corp sub ormont drug and chemical co inc
  • L perrigo co
  • Phoenix laboratories inc
  • Purepac pharmaceutical co
  • Private formulations inc
  • Roxane laboratories inc
  • Sandoz inc
  • Sperti drug products inc
  • Superpharm corp
  • Tablicaps inc
  • Udl laboratories inc
  • Valeant pharmaceuticals international
  • Vitarine pharmaceuticals inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Pfizer laboratories div pfizer inc
  • Central pharmaceuticals inc
  • Alcon laboratories inc
  • Allergan pharmaceutical
  • Taro pharmaceuticals usa inc
  • Merck and co inc
  • Novartis pharmaceuticals corp
  • Pharmafair inc
  • Alcon universal ltd
  • Bausch and lomb pharmaceuticals inc
  • Sola barnes hind
  • Shionogi pharma inc
  • Ucb inc
  • Amneal pharmaceuticals
  • Paddock laboratories inc
  • Pharmaceutical assoc inc
Packagers
  • Adamis Laboratories
  • Aidarex Pharmacuticals LLC
  • Akorn Inc.
  • Alcon Laboratories
  • Allergan Inc.
  • Amend
  • Amneal Pharmaceuticals
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Bausch & Lomb Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • BioMarin Pharmaceuticals Inc.
  • Blansett Pharmacal Co. Inc.
  • Bryant Ranch Prepack
  • C.O. Truxton Inc.
  • Cardinal Health
  • Carlisle Laboratories Inc.
  • Cima Laboratories Inc.
  • Clint Pharmaceutical Inc.
  • Consolidated Midland Corp.
  • Darby Dental Supply Co. Inc.
  • Dexo LLC
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Ethex Corp.
  • Falcon Pharmaceuticals Ltd.
  • Hawthorn Pharmaceuticals
  • Hi Tech Pharmacal Co. Inc.
  • Keene Pharmaceuticals Inc.
  • KV Pharmaceutical Co.
  • Lake Erie Medical and Surgical Supply
  • Laser Pharmaceuticals
  • Lunsco Inc.
  • Lyne Laboratories Inc.
  • Major Pharmaceuticals
  • Marpac
  • Martica Enterprises Inc.
  • Martin Surgical Supply
  • Medisca Inc.
  • Merit Pharmaceuticals
  • MWI Veterinary Supply Co.
  • National Pharmaceuticals
  • Novartis AG
  • Ocusoft
  • OMJ Pharmaceuticals
  • Pacific Pharma Lp
  • Paddock Labs
  • Palmetto Pharmaceuticals Inc.
  • Pfizer Inc.
  • Pharmaceutical Association
  • Pharmacia Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prescript Pharmaceuticals
  • Primedics Laboratories
  • Qualitest
  • Rebel Distributors Corp.
  • San Jose Surgical Supply Inc.
  • Sandoz
  • Sciele Pharma Inc.
  • Shionogi Pharma Inc.
  • Stat Rx Usa
  • Taro Pharmaceuticals USA
  • Teva Pharmaceutical Industries Ltd.
  • UCB Pharma
  • Upstate Pharma LLC
  • Vedco Inc.
  • Vintage Pharmaceuticals Inc.
  • Wa Butler Co.
  • Watson Pharmaceuticals
  • Wockhardt Ltd.
Dosage forms
FormRouteStrength
OintmentTopical
TabletOral5 mg/5mg
TabletOral
SolutionOral5 mg
LiquidOral
SolutionOral
SolutionOral15 mg/5mL
SyrupOral15 mg/5mL
SyrupOral5 mg/5mL
TabletOral5 mg/1
Prices
Unit descriptionCostUnit
Orapred ODT 48 15 mg Dispersible Tablet Box289.42USD box
Pred Forte 1% Suspension 15ml Bottle97.79USD bottle
PrednisoLONE Sodium Phosphate 1% Solution 10ml Bottle72.82USD bottle
Pred Forte 1% Suspension 10ml Bottle68.06USD bottle
Econopred Plus 1% Suspension 10ml Bottle63.44USD bottle
Solu-Medrol Act-O-Vial 1 g/vial61.25USD vial
Solu-Medrol 1 g/vial60.04USD vial
Pediapred 6.7 mg/5ml Solution 120ml Bottle57.77USD bottle
Pred Mild 0.12% Suspension 10ml Bottle44.33USD bottle
Econopred Plus 1% Suspension 5ml Bottle40.99USD bottle
Solu-Medrol Act-O-Vial 500 mg/vial39.96USD vial
Medrol (Pak) 21 4 mg tablet Disp Pack39.3USD disp
Solu-Medrol 500 mg/vial39.17USD vial
Pred Forte 1% Suspension 5ml Bottle37.12USD bottle
Prednisolone sod ph powder36.11USD g
PrednisoLONE Acetate 1% Suspension 15ml Bottle35.46USD bottle
PrednisoLONE Sodium Phosphate 1% Solution 15ml Bottle34.41USD bottle
Pred Mild 0.12% Suspension 5ml Bottle33.98USD bottle
Methylprednisolone Sod Succin. 1 g/vial32.47USD vial
Solu-medrol 1 gm vial24.43USD vial
PrednisoLONE Acetate 1% Suspension 10ml Bottle24.02USD bottle
Solu-medrol (pf) 500 mg vial20.9USD vial
PrednisoLONE Sodium Phosphate 1% Solution 5ml Bottle19.99USD bottle
Methylprednisolone Sod Succin. 500 mg/vial19.48USD vial
PrednisoLONE Acetate 1% Suspension 5ml Bottle15.99USD bottle
Solu-Medrol Act-O-Vial 125 mg/vial15.94USD vial
Solu-medrol 500 mg vial12.9USD vial
Depo-medrol 80 mg/ml vial11.67USD ml
Depo-Medrol 80 mg/ml11.51USD ml
Pred forte 1% eye drops10.32USD ml
Methylprednisolone Acetate 80 mg/ml9.01USD ml
Methylprednisolone Sod Succin. 125 mg/vial8.9USD vial
Depo-Medrol (Preserved) 80 mg/ml8.89USD ml
Orapred odt 30 mg tablet8.34USD tablet
Orapred odt 15 mg tablet7.97USD tablet
Methylprednisolone Acetate (P) 80 mg/ml6.97USD ml
Omnipred 1% eye drops6.78USD ml
Solu-Medrol Act-O-Vial 40 mg/vial6.72USD vial
Depo-medrol 40 mg/ml vial6.41USD ml
Depo-Medrol 40 mg/ml6.01USD ml
Pred Forte 1 % Suspension5.95USD ml
Solu-medrol (pf) 125 mg vial5.83USD vial
Depo-Medrol (Preserved) 40 mg/ml5.75USD ml
Prednisolone ac 1% eye drop5.75USD ml
Prednisol 1% eye drops5.69USD ml
Pred mild 0.12% eye drops5.14USD ml
Medrol 32 mg tablet5.13USD tablet
Methylprednisolone Acetate 40 mg/ml4.71USD ml
Methylprednisolone Acetate (P) 40 mg/ml4.5USD ml
Econopred plus 1% eye drops3.93USD ml
Orapred odt 10 mg tablet3.89USD tablet
Depo-medrol 20 mg/ml vial3.78USD ml
Methylprednisolone Sod Succin. 40 mg/vial3.77USD vial
Prednisolone sod 1% eye drops3.7USD ml
Medrol 16 mg tablet3.5USD tablet
Prednisolone acetate powder3.36USD g
Prednisolone powder3.36USD g
Depo-Medrol 20 mg/ml2.63USD ml
Medrol 8 mg tablet2.3USD tablet
Ratio-Prednisolone 1 % Suspension2.03USD ml
Sandoz Prednisolone Acetate 1 % Suspension2.03USD ml
Pred Mild 0.12 % Suspension2.02USD ml
Medrol 4 mg tablet1.69USD tablet
Medrol 4 mg dosepak1.59USD each
Sandoz Prednisolone Acetate 0.12 % Suspension1.33USD ml
Millipred dp 5 mg dose pack tablet1.18USD tablet
Medrol 2 mg tablet0.84USD tablet
Orapred 15 mg/5 ml solution0.74USD ml
Millipred 5 mg tablet0.59USD tablet
Prelone 15 mg/5 ml syrup0.54USD ml
Prelone 15 mg/5ml Syrup0.47USD ml
PrednisoLONE Sodium Phosphate 15 mg/5ml Solution0.33USD ml
PrednisoLONE Sodium Phosphate 5 mg/5ml Solution0.23USD ml
Prednisolone 5 mg tablet0.14USD tablet
Pediapred 1 mg/ml Liquid0.14USD ml
Pms-Prednisolone 1 mg/ml Liquid0.07USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5178878No1993-01-122010-01-12Us
US6221392No2001-04-242018-04-09Us
US6024981No2000-02-152018-04-09Us
US6740341No2004-05-252019-11-24Us
US7799331No2010-09-212028-10-11Us
US6071523No2000-06-062018-06-03Us
US6399079No2002-06-042018-06-03Us
US5881926No1999-03-162016-03-16Us
US6656482No2003-12-022018-06-03Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)235 °CPhysProp
water solubility223 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.62HANSCH,C ET AL. (1995)
logS-3.21ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.239 mg/mLALOGPS
logP1.66ALOGPS
logP1.27ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)12.59ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity98.49 m3·mol-1ChemAxon
Polarizability38.69 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9918
Blood Brain Barrier+0.9383
Caco-2 permeable-0.5096
P-glycoprotein substrateSubstrate0.7861
P-glycoprotein inhibitor INon-inhibitor0.7847
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.7463
CYP450 2C9 substrateNon-substrate0.8496
CYP450 2D6 substrateNon-substrate0.9138
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9406
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.9418
CYP450 2C19 inhibitorNon-inhibitor0.9253
CYP450 3A4 inhibitorNon-inhibitor0.8902
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9095
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9597
BiodegradationNot ready biodegradable0.925
Rat acute toxicity1.8914 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.95
hERG inhibition (predictor II)Non-inhibitor0.584
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-00di-1910000000-2f59b266e7257ff0e7ad
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0019000000-34782b355045c38d0504
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-002f-0009000000-4a00ac3c2f4930e108cc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0005-0689000000-b0eaba9949ae34d0e571
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dj-0900000000-0a92fbafb31c0170151c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dj-0900000000-856481c7f4d3a6d1ac63
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dj-0900000000-813955b7791f046a3a67
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0900000000-c70a1009bba6e4f3a2c8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0009000000-e4bce0d078573494d8cd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-006w-0905000000-94eb00e6ffa4c56ac51b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dj-0900000000-7797dc6be351391cf57a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dj-0900000000-d156992d517e46c9575d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00r2-0910000000-598b90f7f0f7ba4e13eb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0900000000-eed30fed077e1dfffd3b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-002f-0009000000-0af4f657def15fe9274e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-1920000000-5811b59a6f57222762d7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-06xw-2910000000-84fec77617e1b7a1648b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03dl-0596000000-e0abadaf09054d046b08
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03xu-0595000000-4f8d30df506ea649fc04
MS/MS Spectrum - , positiveLC-MS/MSsplash10-006x-1986000000-d088900fa4c56b9ff51d
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0159-0900000000-01f9c0e6f14839685506

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 3-oxo delta-1,4-steroids / 17-hydroxysteroids / 11-beta-hydroxysteroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols / Cyclic ketones
show 4 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / 20-oxosteroid / Pregnane-skeleton / 3-oxo-delta-1,4-steroid / 3-oxosteroid / Oxosteroid / 11-beta-hydroxysteroid / 11-hydroxysteroid / 17-hydroxysteroid
show 15 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
11beta-hydroxy steroid, 17alpha-hydroxy steroid, glucocorticoid, 20-oxo steroid, 3-oxo-Delta(1),Delta(4)-steroid, 21-hydroxy steroid (CHEBI:8378) / Pregnane and derivatives [Fig] (C07369) / C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030179)

Targets

Details
1. Glucocorticoid receptor
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Ikonomidis I, Tzortzis S, Lekakis J, Paraskevaidis I, Andreadou I, Nikolaou M, Kaplanoglou T, Katsimbri P, Skarantavos G, Soucacos P, Kremastinos DT: Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart. 2009 Sep;95(18):1502-7. doi: 10.1136/hrt.2009.168971. Epub 2009 May 28. [PubMed:19482847]
  2. Boudinot FD, D'Ambrosio R, Jusko WJ: Receptor-mediated pharmacodynamics of prednisolone in the rat. J Pharmacokinet Biopharm. 1986 Oct;14(5):469-93. [PubMed:2879901]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Usui T, Saitoh Y, Komada F: Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7. doi: 10.1248/bpb.26.510. [PubMed:12673034]
  2. Pichard L, Fabre I, Daujat M, Domergue J, Joyeux H, Maurel P: Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol. 1992 Jun;41(6):1047-55. [PubMed:1614409]
  3. Litt J. (2016). Litt's Drug eruption & reaction manual (22nd ed.). CRC Press LLc.

Carriers

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Binder
General Function
Steroid binding
Specific Function
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name
SERPINA6
Uniprot ID
P08185
Uniprot Name
Corticosteroid-binding globulin
Molecular Weight
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Frey BM, Frey FJ: Estimation of transcortin concentration by measurements of plasma protein-binding of prednisolone and by electroimmunodiffusion. Br J Clin Pharmacol. 1982 Feb;13(2):245-9. [PubMed:6800390]
  4. Ko HC, Almon RR, Jusko WJ: Effect of corticosteroid binding globulin on the pharmacokinetics of prednisolone in rats. Pharm Res. 1995 Jun;12(6):902-4. [PubMed:7667198]
  5. Angeli A, Frajria R, De Paoli R, Fonzo D, Ceresa F: Diurnal variation of prednisolone binding to serum corticosteroid-binding globulin in man. Clin Pharmacol Ther. 1978 Jan;23(1):47-53. [PubMed:563315]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Binder
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Pickup ME: Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet. 1979 Mar-Apr;4(2):111-28. doi: 10.2165/00003088-197904020-00004. [PubMed:378499]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019]
  2. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924]

Drug created on June 13, 2005 07:24 / Updated on December 07, 2019 14:25